Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12066196 | 0.91 | — | — | |
| SCHEMBL3778172 | 0.89 | DYRK1A (0.55) | DYRK1AMTNR1AMTNR1BHTR1ADRD2 | |
| SCHEMBL12065370 | 0.87 | KDM4E (0.62) | KDM4EALDH1A1HPGD | |
| SCHEMBL3404323 | 0.85 | ALDH1A1 (0.54) | DYRK1AMTNR1AMTNR1BHTR1ADRD2 | |
| SCHEMBL15595114 | 0.82 | HTR1A (0.53) | MTNR1AMTNR1BHTR1ADRD2HTR2A | |
| SCHEMBL14313796 | 0.81 | TDP1 (0.49) | DYRK1AMTNR1AMTNR1BHTR1ADRD2 | |
| SCHEMBL13730099 | 0.81 | HTR1A (0.46) | MTNR1AMTNR1BHTR1ADRD2HTR2A | |
| SCHEMBL15850810 | 0.81 | KCNH2 (0.48) | MTNR1AMTNR1BHTR1ADRD2HTR2A | |
| SCHEMBL3409598 | 0.80 | KMO (0.61) | KMODYRK1AMTNR1AMTNR1BKDM4E | |
| SCHEMBL15850833 | 0.80 | HTR1A (0.46) | HTR1ADRD2HTR2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254887-B9 | OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-8349826-B2 | Oxazolidinone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-01-08 | — | — | US | disclosed |
| EP-2254887-B1 | OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011148962-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF | 大正製薬株式会社 (JP) | 2011-12-01 | — | — | WO | disclosed |
| US-20100331308-A1 | OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-12-30 | — | — | US | disclosed |
| EP-2254887-A1 | OXAZOLIDINONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009104159-A1 | OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331308-A1 | OXAZOLIDINONE DERIVATIVES | OXA1L, UQCRB, O60361 | KMO 3983/4885DYRK1A 1845/4885MTNR1A 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.